|
If you are having trouble viewing this message, please click here.
To ensure consistent delivery, please be sure to add us to your address book or your safe senders list. |
||||||||||||||||
|
||||||||||||||||
|
U.S. Pharmacist Weekly News Update is a service of
Jobson Medical Information LLC
the publisher of U.S. Pharmacist, 160 Chubb Avenue, Suite 304, Lyndhurst, NJ 07071. To change your address, reply to this message and give us your old and new addresses. Type "Change of Address: U.S. Pharmacist Case Study Challenge" in the subject line.
Click
here if you do not want to receive future emails from U.S.
Pharmacist Weekly News Update.
|
||||||||||||||||
ADMELOG A NEW INSULIN LISPRO OPTION A MEALTIME INSULIN highly similar to Humalog ® in structure, pharmacology, efficacy, safety, and dosing 1-4 FOR DETAILS, VISIT ADMELOGPRO.COM Indication for ADMELOG ® (insulin lispro injection) 100 Units/mL ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adults with type 2 diabetes and adults and children (3 years and older) with type 1 diabetes. Important Safety Information for ADMELOG ® (insulin lispro injection) 100 Units/mL CONTRAINDICATIONS ADMELOG is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin lispro or to any of its excipients. WARNINGS AND PRECAUTIONS Insulin pens and needles must never be shared between patients, even if the needle ...
Comments
Post a Comment